secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xenetic Biosciences, Inc. (XBIO)
CIK:        0001534525
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001683168-23-001681
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1
--------------------------------------------------------------------------------

- Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.
- Cash at year-end totaled $13.1 million, expected to fund operations and pipeline development.
- Royalty payments from Takeda sublicense were ~$1.7M, up 47.1% YoY.
- DNase oncology platform progressing towards first-in-human study combined with checkpoint inhibitors or chemo.
- Appointed oncology and NETs experts Allan Tsung, MD and Jonathan Spicer, MD, PhD to Scientific Advisory Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/0001683168-23-001681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534525/000168316823001681/xenetic_8k-032323.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-001681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer